Affordable Access

deepdyve-link
Publisher Website

Combination therapy with sorafenib and S-1 for renal cell carcinoma producing granulocyte colony-stimulating factor.

Authors
  • Kyono, Yoko
  • Takayama, Tatsuya
  • Kinoshita, Mana
  • Kurita, Yutaka
  • Mugiya, Soichi
  • Baba, Satoshi
  • Ozono, Seiichiro
Type
Published Article
Journal
International journal of clinical oncology
Publication Date
Jun 01, 2011
Volume
16
Issue
3
Pages
275–278
Identifiers
DOI: 10.1007/s10147-010-0126-x
PMID: 20845054
Source
Medline
License
Unknown

Abstract

We present the first case report of the use of sorafenib and S-1 for the treatment of renal cell carcinoma (RCC) producing granulocyte colony-stimulating factor (G-CSF). This entity is clinically rare and has a poor outcome. A 78-year-old Japanese man presented with macrohematuria, left flank pain, and a palpable mass. Laboratory data showed marked leukocytosis with increased serum and urinary G-CSF. The histopathological diagnosis was unclassified RCC. New combination therapy with sorafenib and S-1 exerted a therapeutic effect and apparently decreased serum and urinary G-CSF levels, although the patient died of gastrointestinal perforation. The use of combined sorafenib and S-1 may be worthy of consideration in the treatment of RCC producing G-CSF.

Report this publication

Statistics

Seen <100 times